针对新冠肺炎的放射性治疗药物研究  

Radiopharmaceuticals for the Treatment of COVID-19

作　　者：罗志福[1] 樊彩云[1] 李凤林[1] 陈宝军[1] 刘子华[1] 解清华 LUO Zhifu;FAN Caiyun;LI Fenglin;CHEN Baojun;LIU Zihua;XIE Qinghua(China Institute of Atomic Energy,Beijing 102413,China)

机构地区：[1]中国原子能科学研究院,北京102413

出　　处：《同位素》2022年第1期67-69,共3页Journal of Isotopes

基　　金：中国原子能科学研究院的资金支持

摘　　要：基于核技术在现代医学中有十分广泛的应用,本工作提出用放射性药物治疗新型冠状病毒肺炎或其他冠状病毒引发疾病的颠覆性创新思路。围绕该思路进行了可行性分析、理论计算和实验工作,完成了目标药物分子的设计和制备;进行了其与新冠病毒刺突蛋白受体结合域(RBD)的亲和力以及和新冠病毒假病毒粒子的结合评价;进行了放射性药物分子的制备、在正常小鼠体内的生物分布和急性毒性实验,取得了阶段性研究成果。进一步工作将全面评价放射性药物分子用于治疗新冠肺炎的安全性和有效性,力争为应对突发传染病重大疫情提供核技术新方法。Based on the wide application of nuclear technology in modern medicine,this work proposes a breakthrough idea for the treatment of COVID-19 or diseases induced by other coronavirus with radiopharmaceuticals.The analysis of feasibility,theoretical calculation and experimental works were carried out around this idea,and the design and preparation of the target molecules were completed.Its affinity with SARS-CoV-2 spike protein binding domain(RBD)and its binding with SARS-CoV-2 false virus particles were evaluated.The preparation of radiopharmaceutical molecules,biological distribution in normal mice and acute toxicity experiments were carried out.The effectiveness and safety of the radiopharmaceuticals in the treatment of COVID-19 will be evaluated in further work,which maybe a new nuclear technology for dealing with major infectious diseases.

关 键 词：新冠肺炎 放射性治疗药物 冠状病毒 

分 类 号：TL923[核科学技术—核燃料循环与材料]